Rational use of eculizumab in secondary atypical hemolytic uremic syndrome

Rational use of eculizumab in secondary atypical hemolytic uremic syndrome

BackgroundSecondary atypical hemolytic uremic syndrome (secondary aHUS) is a heterogeneous group of thrombotic microangiopathies (TMA) associated with various underlying conditions. Unlike primary aHUS, there is still no hard evidence on the efficacy of complement blockade in secondary aHUS, since t...

Full description

Bibliographic Details
Main Authors: Lucía Cordero, Teresa Cavero, Eduardo Gutiérrez, Hernando Trujillo, Justo Sandino, Pilar Auñón, Marta Rivero, Enrique Morales
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-01-01
Series:Frontiers in Immunology
Subjects:
eculizumab
complement
renal
atypical hemolytic uremic syndrome
hemolysis
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1310469/full

Similar Items

Similar Items